Medication info
Selvina Tablet (Terbinafine Hydrochloride)

Selvina Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Telcon Rf Pharmaceutical Co., Ltd.
Appearance
White to off-white round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201400914 · Approved 2014.02.28 · Insurance code 625500050

Summary

Main use
Treatment of onychomycosis, dermatomycoses (e.g., tinea pedis and tinea corporis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Adults Administer 125 mg of terbinafine per dose twice daily, or 250 mg per dose once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Administer for usually 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Treatment of toenail infections usually requires 3 months, but may take 6 months or longer in some patients. Treatment may take longer in patients with slow nail growth. Patients with renal impairment For patients with a creatinine clearance of less than 50 mL/min, reduce the daily dose by 1/2.
Child dose
Children: Administer to children 2 years of age and older. Administration is not recommended for children under 2 years of age because there is no experience with its use. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the prescribed duration. Body weight under 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
Telcon Rf Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, dermatomycoses (e.g., tinea pedis and tinea corporis), and tinea capitis

  • Dermatophyte infections caused by dermatophytes
  • tinea pedis
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used in adults to treat dermatophyte infections such as tinea pedis, tinea corporis, and tinea cruris, as well as onychomycosis. It is effective for treating tinea capitis in children. In other words, it is used to improve various skin and nail fungal infections.

How to take

Adult dose

Adults Administer 125 mg of terbinafine per dose twice daily, or 250 mg per dose once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Administer for usually 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Treatment of toenail infections usually requires 3 months, but may take 6 months or longer in some patients. Treatment may take longer in patients with slow nail growth. Patients with renal impairment For patients with a creatinine clearance of less than 50 mL/min, reduce the daily dose by 1/2.

Child dose

Children: Administer to children 2 years of age and older. Administration is not recommended for children under 2 years of age because there is no experience with its use. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the prescribed duration. Body weight under 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This drug should generally not be used in patients with chronic liver disease or active liver disease. A liver function test must be performed before administration, and it should be monitored regularly during treatment, with immediate cessation of use if any abnormal signs are detected. Symptoms that may indicate liver dysfunction include nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, diarrhea, etc. If any of these symptoms occur, the doctor should be informed immediately. Additionally, hepatic failure can rarely occur, so if liver damage is suspected, the medication must be stopped immediately. This medication should not be administered to patients who are hypersensitive to its components, those with chronic or active liver disease, blood disorders, severe renal failure, nursing mothers, or infants under 2 years of age. Since it contains lactose, patients with lactose intolerance or related genetic disorders should also refrain from taking it. Caution is advised when administering to patients with reduced kidney function, the elderly (aged 65 or older), or children weighing less than 20 kg. Serious skin reactions may rarely occur, so if a rash or abnormal symptoms develop, use should be discontinued immediately. Patients with psoriasis or systemic lupus erythematosus should be particularly vigilant when using this medication. During treatment with this drug, liver function, blood tests, skin condition, etc., should be monitored regularly, and if abnormal symptoms appear, consultation with a doctor should occur immediately. Patients should be cautious while driving or operating machinery, as symptoms such as dizziness may occur. This medication may interact with other drugs, particularly those affecting liver metabolism, so consultation with a doctor or pharmacist is recommended if taking other medications. When used in conjunction with oral contraceptives, menstrual irregularities may occur, so caution is advised. Safety during pregnancy has not been established, thus pregnant women or those who might become pregnant should use it cautiously, and breastfeeding mothers should avoid using it. In case of overdose, symptoms such as headache, nausea, abdominal pain, dizziness, etc., may appear, and appropriate treatment should be administered based on the symptoms. This medication should be kept out of reach of children, protected from sunlight, and stored at room temperature. Transferring to another container is not advisable as it may compromise quality.

Side effects

Liver failure, hepatitis, cholestasis, jaundice, rash, pruritus, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasis-like rash, psoriasis exacerbation, hair loss, musculoskeletal reaction, arthralgia, myalgia, weakness, elevated CPK, elevated myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, abdominal discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste loss, taste disorder, dizziness, drowsiness, paresthesia, sensory decrease, decreased attention, insomnia, elevated BUN, frequent urination, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated serum total cholesterol, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent anosmia, hyposmia, eosinophilia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air and kept at a temperature between 1 and 30 degrees Celsius. Proper storage is essential to maintain the efficacy of the drug and prevent deterioration.

Appearance and packaging

Appearance

White to off-white round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.